| Heartland Eye Care, Pc | |
|
121 Briggs Ave N, Park River, ND 58270-0714 | |
| (701) 284-7330 | |
| (701) 284-7332 |
| Full Name | Heartland Eye Care, Pc |
|---|---|
| Type | Facility |
| Speciality | Optometrist |
| Location | 121 Briggs Ave N, Park River, North Dakota |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1932277936 | NPI | - | NPPES |
| 84873HE | Other | MN | BLUE CROSS BLUE SHIELD |
| 339001 | Other | ND | BLUE CROSS BLUE SHIELD |
| 0280490001 | Other | ND | NAS-CIGNA REGION D |
| CH9068 | Other | ND | PALMETTO GBA-RAILROAD MC |
| 60418 | Medicaid | ND |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | (* (Not Available)) | Primary |
| Provider Name | Michelle K Carter |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1497747984 PECOS PAC ID: 1052212396 Enrollment ID: I20040119000562 |
News Archive
MEDNAX, Inc., today announced the acquisition of Burlington Anesthesia PLLC, a physician group practice that provides anesthesia services in Burlington, N.C. and Farhouch Berdjis MD Medical Corp (FBMC), a pediatric cardiology practice in Orange, Calif.
The drawback in the new immunotherapies in multiple sclerosis (MS) includMe severe infections that can be fatal. For example, treatment with natalizumab, which reduces the immune surveillance of the brain, can lead to the development of progressive multifocal leukoencephalopathy (PML), a typically fatal form of viral encephalitis.
An international team of researchers have found that a new blood pressure medication is as effective in reducing cardiovascular death, with fewer side effects than the current treatments offered.
A team of researchers from the United States and Europe has identified more than a dozen genes that may play a role in the etiology of common forms of kidney disease. The team, known as the CKDGen Consortium, examined common variations in DNA sequences in more than 65,000 individuals of European descent. Common variations in several genes were found to be more frequent among people with poor kidney function or chronic kidney disease than in those with normal kidney function.
Peplin, Inc. (ASX:PLI) today announced completion of enrolment in its second Phase 3 clinical trial for the use of PEP005 (ingenol mebutate) Gel to treat actinic (solar) keratoses (AK), a common pre-cancerous skin lesion, on non-head treatment areas, which include the trunk and extremities. This completes enrolment in the final of four pivotal trials planned for the submission of the New Drug Application (NDA) for AK.
› Verified 3 days ago
| Provider Name | Dori Carlson |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1649231192 PECOS PAC ID: 6406999093 Enrollment ID: I20100204000429 |
News Archive
MEDNAX, Inc., today announced the acquisition of Burlington Anesthesia PLLC, a physician group practice that provides anesthesia services in Burlington, N.C. and Farhouch Berdjis MD Medical Corp (FBMC), a pediatric cardiology practice in Orange, Calif.
The drawback in the new immunotherapies in multiple sclerosis (MS) includMe severe infections that can be fatal. For example, treatment with natalizumab, which reduces the immune surveillance of the brain, can lead to the development of progressive multifocal leukoencephalopathy (PML), a typically fatal form of viral encephalitis.
An international team of researchers have found that a new blood pressure medication is as effective in reducing cardiovascular death, with fewer side effects than the current treatments offered.
A team of researchers from the United States and Europe has identified more than a dozen genes that may play a role in the etiology of common forms of kidney disease. The team, known as the CKDGen Consortium, examined common variations in DNA sequences in more than 65,000 individuals of European descent. Common variations in several genes were found to be more frequent among people with poor kidney function or chronic kidney disease than in those with normal kidney function.
Peplin, Inc. (ASX:PLI) today announced completion of enrolment in its second Phase 3 clinical trial for the use of PEP005 (ingenol mebutate) Gel to treat actinic (solar) keratoses (AK), a common pre-cancerous skin lesion, on non-head treatment areas, which include the trunk and extremities. This completes enrolment in the final of four pivotal trials planned for the submission of the New Drug Application (NDA) for AK.
› Verified 3 days ago
| Provider Name | Mark K Helgeson |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1932160132 PECOS PAC ID: 9830234459 Enrollment ID: I20100308000515 |
News Archive
MEDNAX, Inc., today announced the acquisition of Burlington Anesthesia PLLC, a physician group practice that provides anesthesia services in Burlington, N.C. and Farhouch Berdjis MD Medical Corp (FBMC), a pediatric cardiology practice in Orange, Calif.
The drawback in the new immunotherapies in multiple sclerosis (MS) includMe severe infections that can be fatal. For example, treatment with natalizumab, which reduces the immune surveillance of the brain, can lead to the development of progressive multifocal leukoencephalopathy (PML), a typically fatal form of viral encephalitis.
An international team of researchers have found that a new blood pressure medication is as effective in reducing cardiovascular death, with fewer side effects than the current treatments offered.
A team of researchers from the United States and Europe has identified more than a dozen genes that may play a role in the etiology of common forms of kidney disease. The team, known as the CKDGen Consortium, examined common variations in DNA sequences in more than 65,000 individuals of European descent. Common variations in several genes were found to be more frequent among people with poor kidney function or chronic kidney disease than in those with normal kidney function.
Peplin, Inc. (ASX:PLI) today announced completion of enrolment in its second Phase 3 clinical trial for the use of PEP005 (ingenol mebutate) Gel to treat actinic (solar) keratoses (AK), a common pre-cancerous skin lesion, on non-head treatment areas, which include the trunk and extremities. This completes enrolment in the final of four pivotal trials planned for the submission of the New Drug Application (NDA) for AK.
› Verified 3 days ago
| Provider Name | Jaime Alyssa Hoenke |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1124353206 PECOS PAC ID: 7810129459 Enrollment ID: I20140413000002 |
News Archive
MEDNAX, Inc., today announced the acquisition of Burlington Anesthesia PLLC, a physician group practice that provides anesthesia services in Burlington, N.C. and Farhouch Berdjis MD Medical Corp (FBMC), a pediatric cardiology practice in Orange, Calif.
The drawback in the new immunotherapies in multiple sclerosis (MS) includMe severe infections that can be fatal. For example, treatment with natalizumab, which reduces the immune surveillance of the brain, can lead to the development of progressive multifocal leukoencephalopathy (PML), a typically fatal form of viral encephalitis.
An international team of researchers have found that a new blood pressure medication is as effective in reducing cardiovascular death, with fewer side effects than the current treatments offered.
A team of researchers from the United States and Europe has identified more than a dozen genes that may play a role in the etiology of common forms of kidney disease. The team, known as the CKDGen Consortium, examined common variations in DNA sequences in more than 65,000 individuals of European descent. Common variations in several genes were found to be more frequent among people with poor kidney function or chronic kidney disease than in those with normal kidney function.
Peplin, Inc. (ASX:PLI) today announced completion of enrolment in its second Phase 3 clinical trial for the use of PEP005 (ingenol mebutate) Gel to treat actinic (solar) keratoses (AK), a common pre-cancerous skin lesion, on non-head treatment areas, which include the trunk and extremities. This completes enrolment in the final of four pivotal trials planned for the submission of the New Drug Application (NDA) for AK.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Heartland Eye Care, Pc Po Box O, Park River, ND 58270-0714 Ph: (701) 284-7330 | Heartland Eye Care, Pc 121 Briggs Ave N, Park River, ND 58270-0714 Ph: (701) 284-7330 |
News Archive
MEDNAX, Inc., today announced the acquisition of Burlington Anesthesia PLLC, a physician group practice that provides anesthesia services in Burlington, N.C. and Farhouch Berdjis MD Medical Corp (FBMC), a pediatric cardiology practice in Orange, Calif.
The drawback in the new immunotherapies in multiple sclerosis (MS) includMe severe infections that can be fatal. For example, treatment with natalizumab, which reduces the immune surveillance of the brain, can lead to the development of progressive multifocal leukoencephalopathy (PML), a typically fatal form of viral encephalitis.
An international team of researchers have found that a new blood pressure medication is as effective in reducing cardiovascular death, with fewer side effects than the current treatments offered.
A team of researchers from the United States and Europe has identified more than a dozen genes that may play a role in the etiology of common forms of kidney disease. The team, known as the CKDGen Consortium, examined common variations in DNA sequences in more than 65,000 individuals of European descent. Common variations in several genes were found to be more frequent among people with poor kidney function or chronic kidney disease than in those with normal kidney function.
Peplin, Inc. (ASX:PLI) today announced completion of enrolment in its second Phase 3 clinical trial for the use of PEP005 (ingenol mebutate) Gel to treat actinic (solar) keratoses (AK), a common pre-cancerous skin lesion, on non-head treatment areas, which include the trunk and extremities. This completes enrolment in the final of four pivotal trials planned for the submission of the New Drug Application (NDA) for AK.
› Verified 3 days ago
Dr. Dori M. Carlson, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 121 Briggs Ave N, Park River, ND 58270 Phone: 701-284-7330 Fax: 701-284-7332 | |
Dr. Mark K. Helgeson, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 121 Briggs Ave N, Park River, ND 58270 Phone: 701-284-7330 Fax: 701-284-7332 |